Transfusion Medicine/Hemostasis Clinical Trials Network

描述（由申请人提供） 输血医学和止血临床试验网络（TMH CTN）于2002年获得资助，以应对输血医学和止血领域大型多机构临床试验的需求。TMH网络是促进输血医学和止血领域知识和理解的国家资源。该网络将促进对患有止血疾病的儿童和成人的潜在益处的新型管理策略的有效比较;还将评估用于治疗血液病的新型和现有血液疗法和细胞因子。自成立以来，17个受资助研究中心的主要研究者及其合作者成功地开发和实施了这些领域的临床试验。在迄今为止取得的进展的基础上，在未来5年内，TMH CTN建议：1）维护并根据需要进一步开发一个结构，以支持输血医学和止血领域临床试验的开发、实施和进行。这将与作为数据协调中心的新英格兰研究所和NHLBI的项目人员合作完成。2)利用工作和研究监督小组委员会的结构，完成正在进行的试验，并开发，完善和完成本申请中提出的新试验。3)发展合作关系并支持培训机会，以促进拟议临床试验的成功，并进一步推动输血医学和止血领域。位于查佩尔山的北卡罗来纳州大学是17个受资助的地点之一，一直积极参与TMH CTN。Mark Brecher博士（病理学和实验室系）是该研究所的首席研究员。Dr.奈杰尔Key（内科-血液科）是共同主要研究者。他们都积极参与TMH CTN的几个小组。他们还定期参加指导委员会的季度会议。其他TMH研究人员包括两名全职研究护士和一名兼职医疗技术人员。两个TMH CTN协议正在进行中，这是研究人员在这个网站的意图，以支持新的网络协议在未来。 北卡罗来纳州大学查佩尔山评论

DESCRIPTION (provided by applicant) The Transfusion Medicine and Hemostasis Clinical Trial Network (TMH CTN) was funded in 2002, in response to a demonstrated need for large multi-institutional clinical trials in transfusion medicine and hemostasis. The TMH Network is a national resource for the advancement of knowledge and understanding in the field of transfusion medicine and hemostasis. The Network will promote the efficient comparison of novel management strategies of potential benefit for children and adults with hemostatic disorders; and will also evaluate novel as well as existing blood therapies and cytokines for the treatment of hematologic disorders. Since its inception, the principal investigators and their collaborators at the 17 funded sites, have worked successfully to develop and implement clinical trials in these areas. Building on the progress to date, over the next the 5 years, the TMH CTN proposes to: 1) Maintain, and further develop, as needed, a structure to support the development, implementation and conduct of clinical trials in the areas of transfusion medicine and hemostasis. This will be done in collaboration with the New England Research Institutes as Data Coordinating Center, and program staff at NHLBI. 2) Utilizing a structure of working and study oversight subcommittees, complete ongoing trials and develop, refine and complete new trials proposed in this application. 3) Develop collaborative relationships and support training opportunities to facilitate the success of the proposed clinical trials and further the fields of transfusion medicine and hemostasis. The University of North Carolina at Chapel Hill, one of 17 funded sites, has been participating actively in the TMH CTN. Dr. Mark Brecher (Department of Pathology and Laboratory) is the lead principal investigator at UNC. Dr. Nigel Key (Department of Medicine- Hematology Division) is the co-principal investigator. Both of them have actively participated in several subgroups of TMH CTN. They also regularly attend the quarterly Steering Committee meetings. Additional TMH study staff includes two full-time research nurses and one part-time medical technologist. Two TMH CTN protocols are ongoing at UNC, and it is the intention of the investigators at this site to support new network protocols in the future. UNIVERSITY OF NORTH CAROLINA CHAPEL HILL CRITIQUES